Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Senseonics Holdings, Inc.

Senseonics develops and provides the Eversense Continuous Glucose Monitoring (CGM) System, which is a long-term implantable device designed for diabetes management.

Senseonics

Senseonics, Incorporated | 11,715 followers on LinkedIn. Creators of the first and only long-term implantable CGM | Senseonics, Inc. is a medical device startup company in Germantown, Maryland, USA (near Washington, DC) developing transformative glucose monitoring products that are intended to enable people with diabetes to confidently live their lives with ease.   Utilizing breakthrough fluorescence sensing technology, the Senseonics continuous glucose monitoring (&quot;CGM&quot;​) system is being designed to be the first fully implantable CGM that is highly accurate and stable throughout its long sensor life.  

The system consists of a very small sensor implanted under the skin, an external transmitter, and a mobile medical application, which allows for discreet, easy access to real-time glucose measurements without the need for a dedicated receiver.

Technical Executive - Engineering R&D - IoT and AI - Technology Development - Product Management - Program Management - Seeking VP, Director and Sr…

Brian Thomas

Board Member and Audit Committee Chair

Doug Prince

Leading digital innovation at the heart of science and technology

Everett Lee

Medical Device Regulatory Affairs Professional, R&D Scientist, Project and Personnel Manager

Mark Mortellaro, PhD, RAC-Devices, RCC-MDR

Senseonics, Incorporated

We are delighted to announce our new agreement with Ascensia Diabetes Care “We are extremely excited to be partnering with Ascensia, a leader in the global diabetes space. Ascensia is well known for their high-quality CONTOUR products used by more than 10 million patients world-wide to help manage their diabetes. We believe their global commercial infrastructure and commitment to the Eversense systems will drive market adoption while allowing Senseonics to focus on further development of our implanted technology.” – Tim Goodnow

msh id	COM:SENSEONICS
symbol	SENS
name	Senseonics Holdings, Inc.
homepage url	https://www.senseonics.com
country	US
sector	Healthcare
industry	Medical - Devices
market	STOCKS
employee count	132
crunchbase url	-
linkedin url	-
founders	-

market cap	237.15M
enterprise value	-
stage	Post-IPO Equity
raised capital	16M
valuation	-

monthly webtraffic	2.31K
monthly webtraffic growth	-0.81
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	0.15
growth cost of revenue	0.41
growth depreciation and amortization	-0.26
growth ebitda	-0.11
growth ebitda ratio	0.19
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	0.13
growth gross profit ratio	-0.17

COM:SENSEONICS

Senseonics

Last Close

0.32

21/11 21:00

Market Cap

237.15M

Beta: -

Volume Today

4.47M

Avg: -

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	97.99M
cost of revenue	97.99M
depreciation and amortization	1.28M
ebitda	-74.33M
ebitda ratio	-3.32
eps	-0.11
eps diluted	-0.11
operating expenses	78.69M
operating income	-75.6M
operating income ratio	-3.38

accounts receivables	-2.19M
capital expenditure	-350K
cash at beginning of period	35.79M
cash at end of period	75.71M
inventory	8.78M
working capital ttm	128.84M

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-